CXCL14 and head and neck squamous cell carcinoma: Because therapy refractory HPV+ HNSCC cases demonstrate limited antigen presentation and T-cell infiltration into tumors, we hypothesize that CXCL14 (re)introduction could be used as a novel immunotherapeutic.